Honolulu, Hi., USA - June 18, 2014, Honolulu, Hi., USA - Cardax, Inc., a life sciences company, appoints George W. Bickerstaff, Tamar D. Howson, and Terence A. Kelly, as independent members of its board of directors.
Article continues below
Mr. Bickerstaff has been instrumental in establishing the strategic, operating and financial direction of numerous private and public companies. Mr. Bickerstaff was Chief Financial Officer of Novartis Pharma AG located in Basel, Switzerland and is currently Managing Director of M.M. Dillon, a full service investment bank.
Mr. Bickerstaff started his career at General Electric in manufacturing and then moved into finance. He subsequently joined The Dun & Bradstreet Corporation where he held various senior finance positions including Chief Financial Officer of IMS Health, the largest global publicly traded healthcare information services provider. Mr. Bickerstaff holds a B.S. in Engineering and B.A. in Business Administration from Rutgers University.
Ms. Howson is a seasoned business development executive within the pharmaceutical industry. She currently serves as a corporate business development and strategy consultant to biopharmaceutical companies and she serves as a director at Actavis, Idenix, OXiGENE, and Organovo.
Previously, she was a member of the transaction advisory firm, JSB-Partners. Prior to that, she was Executive Vice President, Corporate Business Development at Lexicon Pharmaceuticals. She was also Senior Vice President, Corporate and Business Development at Bristol-Myers Squibb for more than five years.
In addition, Ms. Howson spent nine years at SmithKline Beecham, where she was Senior Vice President and Director, Business Development and managed SmithKline Beecham's venture capital fund, SR-One. Ms. Howson holds an MBA from Columbia University, a M.S. from City College of New York, and a B.S. in Chemical Engineering from the Technion, Israel.
Dr. Kelly is a scientific leader with both Pharma and Biotech experience and a track record of delivering high quality compounds into advanced clinical studies. With nearly twenty years of experience at Boehringer Ingleheim, including serving as Vice President, Department of Medicinal Chemistry, he is well versed in chemistry, disease biology and the enabling technologies needed for innovative and efficient drug discovery from lead identification through clinical development.
In particular, he has extensive hands on drug discovery and development experience in Inflammatory, Cardiovascular and CNS disorders.
Dr. Kelly is currently President and CEO of CoMentis, a venture-backed private biotech company focused on neurodegenerative diseases. Dr. Kelly completed his B.S. degree in Chemistry at Rensselaer Polytechnic Institute and his Ph.D. degree in Chemistry at the University of Texas at Austin. ■